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We report a rare case of pulmonary phaeohyphomycosis in a 49-year-old woman 6 years after kidney transplantation. She presented
with dyspnea, cough, and fatigue. Her chest CT scan revealed nodular opacities in the right upper lung. A fine needle aspirate biopsy
culture yielded Phaeoacremonium and surgical pathology of the biopsy showed chronic inflammation. We successfully treated her
with posaconazole andmanaged drug interactions between posaconazole and tacrolimus.This is the second reported case of biopsy-
proven pulmonary infection by Phaeoacremonium in a kidney transplant recipient and successfully treated with posaconazole.
1. Background
Phaeoacremonium species are well known plant pathogens
causing stunted growth and dieback of various woody hosts
especially grapevines and have been isolated from necrotic
woody tissue of Prunus species [1, 2]. Phaeoacremonium
species are dematiaceous fungi characterized by the pres-
ence of melanin or melanin-like pigments and are widely
distributed in the environment particularly in soil, wood, and
decomposing plant debris. Phaeohyphomycosis is a collective
term for cutaneous, subcutaneous, and systemic disease
caused by dematiaceous fungi. Pulmonary phaeohyphomy-
cosis is a rare opportunistic infection of immunocompro-
mised hosts. A review of 34 cases of dematiaceous fungal
infections in organ transplant recipients revealed an overall
mortality of 57% among patients with systemic disease and
7% among those with skin, soft-tissue, or joint infections [3].
This is only the second case of biopsy-proven pul-
monary infection by Phaeoacremonium in a kidney trans-
plant recipient and the first report of successful treatment
with posaconazole. Moreover, management of drug inter-
actions between posaconazole and tacrolimus was success-
fully done, thereby preventing supratherapeutic levels of
tacrolimus and avoiding kidney injury.
2. Case Report
A 49-year-old Caucasian female who underwent a living
related kidney transplant 6 years before presented with
progressive dyspnea, cough, and fatigue over 6 months that
failed to improve after the administration of several antibiotic
courses. She had been on tacrolimus and prednisone for
maintenance immunosuppression. She lived in a rural area,
had exposure to chicken sheds and barns, andwas a gardener.
A chest CT scan revealed nodular opacities in the right
upper lobe (Figure 1(a)), and she underwent bronchoscopy
with bronchoalveolar lavage and transbronchial fine needle
aspiration biopsy of the right upper lobe nodules.
Phaeoacremonium species grew from the biopsy culture
within four days of incubation. Identification was assigned
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Figure 1: (a) Chest CT scan before starting posaconazole showing reticulonodular opacities in the right upper lobe. (b) CT scan one month














































































































Tacrolimus 1mg Q day and posaconazole 200mg QID
Tacrolimus 1mg Q day and posaconazole 400mg BID
Figure 2: Graph showing serum creatinine and blood tacrolimus levels before, during, and after posaconazole treatment with tacrolimus
dose adjustments.
based onmacroscopic andmicroscopicmorphology. Initially,
the surface of the mold was olive in color, becoming greyish-
black upon subculture. The texture was velvety, and the
reverse was black. Microscopically, pigmented hyphae with
tapering, funnel-shaped phialideswere observed, and conidia
were hyaline and oblong, forming clusters at the tip of the
phialides. Macroscopic and microscopic morphology was
consistent with Phaeoacremonium species. Surgical pathol-
ogy of the biopsy showed chronic inflammation but no fungal
hyphae. Culture for acid fast bacilli from the biopsy specimen
was negative for mycobacteria. Culture of bronchial fluid
yielded Dactylaria constricta and fewMycobacterium avium-
intracellulare complex.
Given that her biopsy culture yielded Phaeoacremonium
and showed chronic inflammation, we started oral posacona-
zole 200mgQID and reduced her tacrolimus dose from 2mg
BID to 1mg Q day. A repeat chest CT scan one month after
the institution of antifungal therapy showed improvement
(Figure 1(b)), and she reported reduced cough and shortness
of breath. Two months after commencing treatment, we
changed her posaconazole dose to 400mg BID for greater
ease of administration. She received posaconazole for 4
months and her symptoms resolved (Figure 2).
3. Discussion
To et al. reported the first case of biopsy-proven Phaeoacre-
monium parasiticum lung infection in a kidney trans-
plant recipient. In contrast to our case, the patient was
severely immunocompromised due to chemotherapy for
posttransplant lymphoproliferative disease. He showed ini-
tial improvement with voriconazole and caspofungin but
succumbed after a prolonged period of neutropenic fever.
Shah et al. described a case of probable Phaeoacremonium
lung infection in a lung transplant recipient. The patient
developed cavitary lung nodules in the native lung a few
months after single lung transplantation. Biopsy of one of
the nodules showed chronic inflammation with possible
granulomatous lesions. Phaeoacremonium parasiticum grew
only from the bronchoalveolar lavage culture but not from the
biopsy culture.The patient improved after the administration
of voriconazole and caspofungin [21, 26].
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Table 1: Skin and subcutaneous infection, osteomyelitis, endophthalmitis, and onychomycosis due to Phaeoacremonium species.
Number Reference Species Age/sex Underlyingcondition Clinical disease Treatment Outcome
1 Padhye et al.,1998 [4] P. inflatipes 83/F None
Subcutaneous infection
of the foot Excision
Complete
healing









3 Kitamura et al.,2000 [6] P. parasiticum 59/F None
Subcutaneous nodule
below the knee Excision
Complete
healing
4 Guarro et al.,2003 [7] P. aleophilum 19/M None




















Olecranon bursitis ExcisionItraconazole Resolved





8 Hemashettar etal., 2006 [10] P. krajdenii 41/M None Mycetoma
Itraconazole
Debridement Recurred










11 Farina et al.,2007 [13] P. parasiticum 41/M Kidney transplant
Subcutaneous nodule on
the forefinger Excision Resolved


























16 Choi et al., 2011[18]
Phaeoacremonium
species 54/M Renal transplant
Subcutaneous mass on
the third finger Excision Resolved






Nodule on the leg ExcisionItraconazole Resolved







19 To et al., 2012[21] P. parasiticum 69/M Diabetes mellitus







20 Guarro et al.,2006 [22] P. venezuelense 28/M
Chronic myeloid
leukemia Subcutaneous mycoses Surgical excision Not known
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Table 2: Invasive and disseminated infections due to Phaeoacremonium species.
Number Reference Species Age/sex Underlyingcondition Clinical disease Treatment Outcome










Aplastic anemia Fungemia Amphotericin B Died
23 Baddley et al.,2006 [9] P. parasiticum 31/F Aplastic anemia Fungemia, skin lesions Amphotericin B Died















26 Shah et al., 2013[26] P. parasiticum 74/M Lung transplant








49 y/o Renal transplant Multiple brain abscesses Voriconazole Improved
28 Present case Phaeoacremoniumspecies 49/F Renal transplant Lung nodules Posaconazole Improved
Phaeoacremonium species are typically isolated from
thorns, wood, and soil. Human infection can be caused by
traumatic implantation or occurs in the setting of immuno-
compromising conditions. Twenty-seven cases of human
infections with Phaeoacremonium species have been reported
in the literature. In immunocompetent hosts, Phaeoacremo-
nium has been reported to cause subcutaneous phaeohy-
phomycosis, osteomyelitis, endophthalmitis, and onychomy-
cosis. Successful outcomes have been achieved with debride-
ment and antifungals (Table 1). In immunocompromised
patients, Phaeoacremonium causes more severe disease and
has been reported to cause endocarditis, brain abscesses,
cavitary lung nodules, and disseminated infections. Dissem-
inated infections in severely immunocompromised hosts are
associated with poor outcomes and death (Table 2).
The other dematiaceous fungus isolated from this patient
was Dactylaria constricta. It grew only from culture of
bronchial fluid and not from the biopsy. Mycobacterium
avium-intracellulare complex (MAC) also grew only from
the culture of bronchial fluid. Given our patient’s exposure
history (gardening, exposure to sheds and barns) and no
growth of these organisms from the biopsy specimen, it is
likely that these organisms were merely colonizers of her
respiratory tract and not pathogens. Moreover, resolution of
her illness without treatment forMAC suggests that it was not
a pathogen.
There is no standard antifungal regimen described for
Phaeoacremonium in the literature. Posaconazole is the most
recently approved triazole with an extended spectrum of
activity against a wide variety of fungi. Posaconazole was
chosen over other azoles because it is well tolerated and has
a favorable side effect profile and a low potential of drug
interactions compared to other azoles. Posaconazole inhibits
the metabolism of calcineurin inhibitors. Failure to adjust
tacrolimus dosing can result in supratherapeutic levels of
tacrolimus and harm the kidney [28]. Our patient responded
well to the treatment with no relapse of infection during 4
years of follow-up. Her kidney allograft continues to function
well, with creatinine levels ranging between 1 and 1.3mg/dL.
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